Prolonged-Release Nifedipine Tablets Bp 20 Mg Tablet

What is Prolonged-Release Nifedipine Tablets Bp 20 Mg Tablet?

Prolonged-Release Nifedipine Tablets Bp 20 Mg Tablet is an oral prolonged-release formulation containing nifedipine 20 mg. Nifedipine is a dihydropyridine calcium-channel blocker used in the management of hypertension and, where clinically indicated, the prevention of chronic stable angina. The prolonged-release dosage form is designed to provide controlled delivery of nifedipine.

Uses / Indications

Prolonged-release nifedipine may be indicated for:

• Management of hypertension
• Prevention of chronic stable angina pectoris
• Long-term cardiovascular therapy when a calcium-channel blocker is clinically appropriate

It is not intended for rapid treatment of an acute angina attack.

Benefits

• Helps lower elevated blood pressure through arterial vasodilation.
• Reduces peripheral vascular resistance.
• Produces vasodilation in the coronary circulation.
• May help reduce the frequency of anginal symptoms in appropriately selected patients.
• The prolonged-release formulation provides controlled delivery of nifedipine over an extended period.

Side Effects

Common Side Effects

Possible adverse effects include:

• Headache
• Dizziness
• Flushing
• Palpitations
• Peripheral oedema, particularly ankle swelling
• Constipation
• Nausea
• Fatigue

Less Common or Serious Side Effects

Medical attention should be sought for:

• Severe or persistent dizziness or low blood pressure
• Fainting
• Significant or worsening chest pain
• Breathing difficulty
• Significant allergic reactions
• Marked changes in heartbeat
• Severe or unusual skin reactions

The occurrence of adverse effects can vary between individuals and formulations.

How Does It Work?

Nifedipine

Nifedipine is a dihydropyridine calcium-channel blocker. It reduces the movement of calcium ions into vascular smooth-muscle cells, resulting primarily in relaxation of arterial smooth muscle. This widens peripheral arteries, reduces peripheral vascular resistance, and lowers blood pressure. Coronary vasodilation also contributes to its use in chronic stable angina.

Prolonged-Release Formulation

The prolonged-release formulation is designed to release nifedipine in a controlled manner. This differs from immediate-release formulations and supports sustained therapeutic exposure according to the specific product’s approved release characteristics.

Dosage Guidelines

• The exact dose and treatment duration should follow the approved product information and the recommendation of a qualified healthcare professional.
• Dose selection depends on the indication, blood-pressure response, age, concurrent medicines, and individual clinical factors.
• The 20 mg strength may be used according to the dosing regimen specified for the particular prolonged-release product.
• Swallow prolonged-release tablets whole with water.
• Do not crush, chew, divide, or dissolve the tablet unless specifically permitted by the approved product information.
• Do not independently increase, decrease, or discontinue treatment.

When Not to Use

Nifedipine should not be used in patients with known hypersensitivity to nifedipine, other dihydropyridines where cross-sensitivity is relevant, or applicable formulation components.

Depending on the specific prolonged-release formulation, contraindications may include cardiogenic shock, clinically significant aortic stenosis, unstable angina, certain recent myocardial-infarction situations, and acute angina attacks. Rifampicin should not be co-administered with certain nifedipine prolonged-release products because it can markedly reduce nifedipine exposure.

Drug / Product Interactions

Clinically important interactions may occur with:

• Other antihypertensive medicines due to additive blood-pressure-lowering effects
• Beta-blockers
• CYP3A4 inhibitors, which may increase nifedipine exposure
• CYP3A4 inducers, which may reduce nifedipine exposure
• Rifampicin
• Certain macrolide antibiotics
• Certain azole antifungals
• Certain anticonvulsants
• Other medicines that may substantially affect blood pressure

A complete medication review should be performed before treatment.

Safety Advice

• Blood pressure: Monitor blood pressure as advised by a healthcare professional.
• Dizziness: Dizziness or excessive blood-pressure reduction may affect driving or operating machinery.
• Heart conditions: Patients with heart failure or impaired cardiac function require appropriate medical supervision.
• Liver impairment: Nifedipine is primarily metabolised by the liver; dose adjustment or additional monitoring may be necessary in hepatic impairment.
• Pregnancy: Use during pregnancy should be based on an appropriate medical assessment.
• Breastfeeding: Discuss use with a qualified healthcare professional.
• Elderly patients: Individual dose selection and monitoring may be required.
• Children: Safety and efficacy have not been established for many prolonged-release nifedipine formulations in patients below 18 years.
• Overdose: If an overdose is suspected, seek immediate medical attention or contact an appropriate poison-control or emergency medical service.

General Instructions

• Take the medicine exactly as prescribed.
• Swallow the prolonged-release tablet whole with water.
• Do not crush or chew the tablet.
• Avoid grapefruit juice unless the approved product information specifically permits it, because grapefruit can affect nifedipine exposure.
• Maintain the prescribed dosing schedule.
• If a dose is missed, take it when remembered unless it is close to the next scheduled dose; do not double the dose unless instructed.
• Do not stop long-term cardiovascular treatment without professional guidance.

Special Dietary / Lifestyle Tips

• Follow a balanced diet appropriate for cardiovascular health.
• Limit excessive dietary sodium where medically appropriate.
• Maintain physical activity according to individual medical advice.
• Avoid excessive alcohol intake if it increases dizziness or blood-pressure changes.
• Monitor blood pressure regularly when advised.
• Maintain adherence to other prescribed cardiovascular medicines and lifestyle measures.

Comparison with Other Treatments

Nifedipine belongs to the dihydropyridine calcium-channel blocker class. Other commonly used antihypertensive classes include ACE inhibitors, angiotensin-receptor blockers, beta-blockers, and diuretics.

Treatment selection depends on the indication, blood-pressure response, cardiovascular risk, coexisting conditions, tolerability, and other medicines. Prolonged-release nifedipine provides controlled delivery of nifedipine rather than the release characteristics of an immediate-release formulation.

Precautions & Warnings

• Use only according to approved product information and professional medical advice.
• Monitor for excessive blood-pressure reduction, particularly when used with other antihypertensive medicines.
• Use caution in patients with significant hypotension or reduced cardiac reserve.
• Patients with hepatic impairment may require closer monitoring and dose adjustment.
• Check for CYP3A4-related interactions before treatment.
• Prolonged-release nifedipine should not be used for rapid relief of acute angina.
• Seek urgent medical attention for severe or persistent chest pain, fainting, severe breathing difficulty, or other serious symptoms.

Can I Use It With Other Medicines?

Generally Compatible With

Nifedipine may be prescribed with other antihypertensive medicines, including certain beta-blockers and other cardiovascular treatments, when clinically appropriate. Such combinations may have additive blood-pressure-lowering effects and should be appropriately monitored.

Use With Caution / Avoid

Particular attention is required when nifedipine is used with:

• Rifampicin
• Strong CYP3A4 inhibitors or inducers
• Certain macrolide antibiotics
• Certain azole antifungals
• Certain anticonvulsants
• Other medicines capable of significantly lowering blood pressure

The complete medication list should be reviewed before initiating or changing treatment.

Storage

Store according to the storage conditions stated on the approved product label and package insert.

• Keep the product in its original packaging.
• Protect from excessive heat and moisture.
• Keep properly closed and protected from unsuitable environmental conditions.
• Keep out of reach of children.
• Do not use after the expiry date.
• Product-specific storage requirements should be confirmed against the approved product specification.

Frequently Asked Questions

1. What is Prolonged-Release Nifedipine 20 mg used for?

It is used in the management of hypertension and, where clinically appropriate, for the prevention of chronic stable angina.

2. What type of medicine is nifedipine?

Nifedipine is a dihydropyridine calcium-channel blocker that primarily relaxes arterial smooth muscle and reduces vascular resistance.

3. Is Prolonged-Release Nifedipine suitable for acute chest pain?

No. Prolonged-release nifedipine is not intended for rapid treatment of an acute angina attack. Sudden or severe chest pain requires appropriate urgent medical assessment.

4. Can the 20 mg prolonged-release tablet be crushed or chewed?

Prolonged-release tablets should generally be swallowed whole because crushing or chewing can alter their release characteristics. Follow the specific approved product instructions.

5. Can nifedipine be taken with other blood-pressure medicines?

It may be prescribed with other antihypertensive medicines, but additive blood-pressure-lowering effects can occur. Such combinations should be used according to professional guidance.

6. What are common side effects of nifedipine?

Headache, dizziness, flushing, palpitations, peripheral oedema, constipation, nausea, and fatigue may occur.

7. Can grapefruit juice be taken with prolonged-release nifedipine?

Grapefruit juice can affect nifedipine exposure and is therefore generally avoided with prolonged-release nifedipine products unless the approved product information states otherwise.

8. Can nifedipine interact with other medicines?

Yes. Nifedipine is metabolised through CYP3A4, so medicines that inhibit or induce this enzyme can alter nifedipine exposure. Rifampicin and several other medicines can therefore require particular consideration.